With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Despite market gains, Harbor Long-Term Growers ETF returned 6.90% (NAV) in Q3. Read the full report to understand key drivers ...

Following a Wednesday morning event at Alnylam Pharmaceuticals on Commerce Way, Gov. Maura Healey spoke with The Sun ...

Norgine, a leading European specialty pharmaceutical company, today announced an exclusive licensing agreement under which ...

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced the nomination of CID-165, a first-in-class, ...

Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

Blossom Social ("Blossom"), the social investing network used by more than half a million retail investors, today announced its inclusion on TechTO's 2025 Canadian Rocketships list, which recognizes ...

The Scottish investment trust has warned the possibility of its board being ousted this time has increased significantly ...

The Scottish investment trust has warned the possibility of its board being ousted this time has increased significantly ...